CWA
CORT icon

Clearview Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

Clearview Wealth Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,382
Closed -$362K – 100
2024
Q1 		$362K Buy
+14,382
New +$340K 0.37% 65
2023
Q4 		– Sell
-25,258
Closed -$688K – 113
2023
Q3 		$688K Buy
25,258
+25,178
+31,473% +$729K 0.85% 43
2023
Q2 		$1.78K Sell
80
-34,195
-100% -$787K ﹤0.01% 545
2023
Q1 		$742K Buy
+34,275
New +$751K 0.75% 37

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Clearview Wealth Advisors's CORT Position: Q2 2024 in Review

Clearview Wealth Advisors sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 14,382 shares — an estimated $362K sold.

Clearview Wealth Advisors first reported a position in CORT in Q1 2023 and held it in 4 quarters. The position peaked at $742K in Q1 2023. 286 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • Clearview Wealth Advisors reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Clearview Wealth Advisors sold 14,382 Corcept Therapeutics shares in Q2 2024, an estimated $362K.
  • Clearview Wealth Advisors first reported a position in Corcept Therapeutics in Q1 2023 and held it in 4 quarters.
  • Clearview Wealth Advisors's Corcept Therapeutics position peaked at $742K in Q1 2023.
  • 286 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on Clearview Wealth Advisors's 13F filing for Q2 2024, filed 1 Aug 2024.